Pupillometer Market Size, Share & Trends Report

Pupillometer Market Size, Share & Trends Analysis Report By Mobility (Table-top, Hand-held), By Type (Video, Digital), By End Use (Hospitals, Eye Clinics), By Application (Ophthalmology, Oncology), By Region, And Segment Forecasts, 2023 - 2030

Report ID: GVR-4-68038-850-3
Number of Pages: 140
Format: Electronic (PDF)

Historical Range: 2017 - 2021
Industry: Healthcare

Market Segmentation

Pupillometer Mobility Outlook (Revenue, USD Million, 2017 - 2030)
- Table-top
- Hand-held
Pupillometer Type Outlook (Revenue, USD Million, 2017 - 2030)
- Video
- Digital
Pupillometer End-Use Outlook (Revenue, USD Million, 2017 - 2030)
- Hospitals
- Eye Clinics
- Others
Pupillometer Application Outlook (Revenue, USD Million, 2017 - 2030)
- Ophthalmology
- Neurology
- Oncology
- Others
Pupillometer Regional Outlook (Revenue, USD Million, 2017 - 2030)
- North America
  - North America Mobility Outlook (USD Million) 2017 - 2030
    - Table-top
    - Hand-held
  - North America Type Outlook (USD Million) 2017 - 2030
    - Video
    - Digital
  - North America End-Use Outlook (USD Million, 2017 - 2030)
    - Hospitals
    - Eye Clinics
    - Others
  - North America Application Outlook (USD Million, 2017 - 2030)
    - Ophthalmology
    - Neurology
    - Oncology
    - Others
  - U.S.
    - U.S. Mobility Outlook (USD Million 2017 - 2030)
      - Table-top
      - Hand-held
    - U.S. Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - U.S. End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - U.S. Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Canada
    - Canada Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Canada Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Canada End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Canada Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
- Europe
  - Europe Mobility Outlook (USD Million, 2017 - 2030)
    - Table-top
    - Hand-held
  - Europe Type Outlook (USD Million, 2017 - 2030)
    - Video
    - Digital
  - Europe End-Use Outlook (USD Million, 2017 - 2030)
    - Hospitals
    - Eye Clinics
    - Others
  - Europe Application Outlook (USD Million, 2017 - 2030)
    - Ophthalmology
    - Neurology
    - Oncology
    - Others
  - UK
    - UK Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - UK Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - UK End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - UK Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Germany
    - Germany Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Germany Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Germany End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Germany Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - France
    - France Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - France Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - France End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - France Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Italy
    - Italy Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Italy Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Italy End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Italy Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Spain
    - Spain Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Spain Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Spain End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Spain Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Denmark
    - Denmark Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Denmark Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Denmark End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Denmark Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Sweden
    - Sweden Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Sweden Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Sweden End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Sweden Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Switzerland
    - Switzerland Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Switzerland Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Switzerland End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Switzerland Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Norway
    - Norway Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Norway Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Norway End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Norway Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Poland
    - Poland Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Poland Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Poland End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Poland Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
- Asia Pacific
  - Asia Pacific Mobility Outlook (USD Million, 2017 - 2030)
    - Table-top
    - Hand-held
  - Asia Pacific Type Outlook (USD Million, 2017 - 2030)
    - Video
    - Digital
  - Asia Pacific End-Use Outlook (USD Million, 2017 - 2030)
    - Hospitals
    - Eye Clinics
    - Others
  - Asia Pacific Application Outlook (USD Million, 2017 - 2030)
    - Ophthalmology
    - Neurology
    - Oncology
    - Others
  - China
    - China Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - China Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - China End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - China Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Japan
    - Japan Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Japan Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Japan End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Japan Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - India
    - India Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - India Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - India End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - India Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Thailand
    - Thailand Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Thailand Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Thailand End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Thailand Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - South Korea
    - South Korea Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - South Korea Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - South Korea End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - South Korea Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Indonesia
    - Indonesia Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Indonesia Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Indonesia End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Indonesia Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Australia
    - Australia Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Australia Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Australia End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Australia Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Hong Kong
    - Hong Kong Mobility Outlook (Revenue in USD, 2017 - 2030)
      - Table-top
      - Hand-held
    - Hong Kong Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Hong Kong End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Hong Kong Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Philippines
    - Philippines Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Philippines Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Philippines End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Philippines Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Malaysia
    - Malaysia Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Malaysia Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Malaysia End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Malaysia Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
- Latin America
  - Latin America Mobility Outlook (USD Million, 2017 - 2030)
    - Table-top
    - Hand-held
  - Latin America Type Outlook (USD Million, 2017 - 2030)
    - Video
    - Digital
  - Latin America End-Use Outlook (USD Million, 2017 - 2030)
    - Hospitals
    - Eye Clinics
    - Others
  - Latin America Application Outlook (USD Million, 2017 - 2030)
    - Ophthalmology
    - Neurology
    - Oncology
    - Others
  - Brazil
    - Brazil Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Brazil Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Brazil End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Brazil Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Mexico
    - Mexico Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Mexico Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Mexico End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Mexico Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Argentina
    - Argentina Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Argentina Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Argentina End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Argentina Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Colombia
    - Colombia Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Colombia Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Colombia End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Colombia Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Chile
    - Chile Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Chile Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Chile End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Chile Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
- Middle East and Africa
  - Middle East and Africa Mobility Outlook (USD Million 2017 - 2030)
    - Table-top
    - Hand-held
  - Middle East and Africa Type Outlook (USD Million, 2017 - 2030)
    - Video
    - Digital
  - Middle East and Africa End-Use Outlook (USD Million, 2017 - 2030)
    - Hospitals
    - Eye Clinics
    - Others
  - Middle East and Africa Application Outlook (USD Million, 2017 - 2030)
    - Ophthalmology
    - Neurology
    - Oncology
    - Others
  - South Africa
    - South Africa Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - South Africa Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - South Africa End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - South Africa Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Saudi Arabia
    - Saudi Arabia Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Saudi Arabia Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Saudi Arabia End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
  - UAE
    - UAE Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - UAE Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - UAE End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - UAE Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Kuwait
    - Kuwait Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Kuwait Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Kuwait End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Kuwait Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others
  - Qatar
    - Qatar Mobility Outlook (USD Million, 2017 - 2030)
      - Table-top
      - Hand-held
    - Qatar Type Outlook (USD Million, 2017 - 2030)
      - Video
      - Digital
    - Qatar End-Use Outlook (USD Million, 2017 - 2030)
      - Hospitals
      - Eye Clinics
      - Others
    - Qatar Application Outlook (USD Million, 2017 - 2030)
      - Ophthalmology
      - Neurology
      - Oncology
      - Others

Pupillometer Market Dynamics

Drivers: Rise In The Prevalence Of Eye Diseases

Globally, visual impairment and blindness are primarily caused by eye conditions such as cataracts, glaucoma, age-related macular degeneration, and diabetic retinopathy. The growing elderly population is leading to a corresponding rise in these visual ailments. Furthermore, lifestyle changes have led to an increase in diseases such as diabetes and hypertension, which can also cause visual impairment. According to a 2019 WHO report, around 2.2 million people worldwide suffer from eye disorders, with 1 million cases that could have been prevented or may still be undiagnosed. The most frequently reported eye disorders include presbyopia (826 million cases), refractive error (123.7 million), glaucoma (6.9 million), cataracts (65.2 million), corneal opacities (4.2 million), trachoma (2 million), and diabetic retinopathy (3 million). In the U.S., nearly 1.3 million individuals over the age of 40 are legally blind, defined as having a best-corrected visual acuity of 20/200 or worse in the better-seeing eye. Over 2.9 million people in the same age group have low vision, defined as having a best-corrected visual acuity worse than 20/40, excluding those who are legally blind. Around 4.2 million people over 40 are visually impaired, defined as having a best-corrected visual acuity worse than 20/40 in the better-seeing eye, including both those with low vision and those who are legally blind.

Favourable Government Policies

The market for visual impairment solutions is expected to grow, driven by increased government initiatives that aim to raise awareness about these conditions. According to the World Health Organization, in 2017, there were 180 million people worldwide with visual disabilities. Among them, 40 to 45 million were blind and unable to function independently, necessitating social and vocational support. The rise in visual impairment cases also presents social and economic challenges, especially in developing economies where 90% of the population is visually impaired. About 60% of these individuals are in China, sub-Saharan Africa, and India. Cataracts are the cause of blindness in approximately 50% of these cases, with the remainder suffering from conditions such as trachoma, glaucoma, onchocerciasis, and other child-affecting disorders. The increase in the overall elderly population is the primary contributor to the high global burden of blindness, despite efforts to control the growing prevalence of trachoma. If additional measures were not implemented, the global burden of blindness was expected to double by 2020, particularly in developing economies. VISION 2020 is a global campaign that aims to educate governments and the public about the consequences of blindness. International decision-makers and NGOs need to be persuaded that the human and financial resources allocated for the eradication of blindness are worthwhile investments that will yield returns.

Restrains: Shortage Of Skilled Professionals

Every year in the U.S., there are about 80 specialized training positions available in ophthalmology. However, the country only has 64 ophthalmologists, which is a part of the problem. Compared to the U.S., where there is one ophthalmologist for every 20,000 people, the number of ophthalmologists per person is ten times higher. In terms of global distribution, 23 countries have less than one ophthalmologist per million people; 30 countries have between one and less than four; 48 countries have between four and less than 25; 74 countries have between 25 and less than 100; and 18 countries have more than 100 ophthalmologists per million people. According to a study by the Association for Research in Vision and Ophthalmology published in June 2022, there were approximately 18,500 practicing ophthalmologists in the U.S. However, the American Association of Medical Colleges predicts that by 2025, there will be a shortage of ophthalmology providers. A similar trend is expected with an anticipated shortage of neurologists in the coming years, which could hinder market growth. For example, a 2022 report by the Association of American Medical Colleges on physician supply and demand suggests that the industry could face a shortage of up to 48,000 primary care physicians and up to 77,100 specialists. Factors such as a rapidly growing population, advancements in neurological treatment, and neurologist burnout are contributing to the shortage of neurologists.

What Does This Report Include?

This section will provide insights into the contents included in this pupillometer market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Pupillometer market qualitative analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Pupillometer market quantitative analysis

Market size, estimates, and forecast from 2017 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.